Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $335,787.06 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,206 shares of the business’s stock in a transaction that occurred on Friday, October 4th. The shares were sold at an average price of $27.51, for a total value of $335,787.06. Following the transaction, the chief executive officer now owns 1,036,523 shares of the company’s stock, valued at $28,514,747.73. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Wednesday, October 9th, Samuel Kintz sold 16,710 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.15, for a total value of $470,386.50.
• On Monday, October 7th, Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.50, for a total transaction of $75,075.00.
• On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.54, for a total transaction of $14,486.04.
• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.56, for a total value of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.92, for a total value of $299,040.00.

Enliven Therapeutics Trading Down 4.4 %

ELVN stock opened at $26.97 on Friday. The firm’s 50-day moving average is $23.34 and its two-hundred day moving average is $22.22. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -13.97 and a beta of 1.10. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $28.62.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. On average, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $37.00 price target on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Institutional Trading of Enliven Therapeutics

Several institutional investors have recently modified their holdings of ELVN. Janus Henderson Group PLC raised its position in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock worth $12,604,000 after acquiring an additional 305,397 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $9,657,000. Marshall Wace LLP acquired a new stake in Enliven Therapeutics during the second quarter valued at approximately $4,489,000. Baker BROS. Advisors LP bought a new stake in Enliven Therapeutics during the first quarter worth approximately $2,020,000. Finally, Bank of New York Mellon Corp grew its position in Enliven Therapeutics by 49.2% in the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock worth $2,667,000 after buying an additional 37,632 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.